Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK1 | P53355 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747470 | 0.89 | HDAC6 (0.33) | DAPK1SLC29A1HDAC6PDE10AHPGD | |
| SCHEMBL6745579 | 0.88 | DAPK1 (0.34) | DAPK1SLC29A1HDAC6PDE10AHPGD | |
| SCHEMBL6750499 | 0.88 | PDE10A (0.36) | DAPK1HDAC6PDE10AHPGDHRH4 | |
| SCHEMBL6749417 | 0.88 | FGFR1 (0.42) | DAPK1HDAC6HPGDFGFR1FGFR4 | |
| SCHEMBL6749471 | 0.86 | DAPK1 (0.33) | DAPK1SLC29A1HDAC6PDE10AHPGD | |
| SCHEMBL6748080 | 0.86 | HDAC6 (0.35) | HDAC6 | |
| SCHEMBL6749165 | 0.85 | HDAC6 (0.37) | DAPK1SLC29A1HDAC6FGFR1FGFR4 | |
| SCHEMBL6747287 | 0.85 | FGFR1 (0.32) | DAPK1HDAC6PDE10AHPGDFGFR1 | |
| SCHEMBL6747701 | 0.84 | PDE10A (0.33) | DAPK1SLC29A1HDAC6PDE10AHPGD | |
| SCHEMBL6752024 | 0.84 | PDE10A (0.54) | PDE10AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | DAPK1 1305/4885SLC29A1 848/4885HDAC6 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.